Portfolio Alerts Watch List Cart

Pharmaceutical

Refine Search

Product Compare (0)
A
Auro Laboratories Ltd
Score 48/100• Decent
Auro Laboratories Ltd shows potential but faces challenges in growth consistency and market valuation.
Company’s Health53/100
Valuation 40/100 · PB 3.6152
Technical Avoid
1M 24.212% 6M -7.516% 1Y 7.484%
Confidence100%
No promoter pledge
Weak ROE
#211
View details ➜
A
Astrazeneca Pharma India Ltd
Score 48/100• Decent
Astrazeneca Pharma India Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health90/100
Valuation 20/100 · PB 29.7105
Technical Avoid
1M -0.022% 6M -10.201% 1Y 37.661%
Confidence100%
Low leverage (D/E)No promoter pledge
Thin margins
#212
View details ➜
A
Astonea Labs Ltd
Score 48/100• Risky
Astonea Labs Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health80/100
Valuation 20/100 · PB 8.7354
Technical Avoid
1M 13.732% 6M 5.882% 1Y 12.79%
Confidence100%
No promoter pledgeDecent revenue growth
High debt/equityThin margins
#213
View details ➜
A
Astal Laboratories Ltd
Score 48/100• Risky
Astal Laboratories Ltd shows potential but faces significant risks and challenges in growth and profitability.
Company’s Health74/100
Valuation 60/100 · PB 2.4541
Technical Avoid
1M -11.8% 6M -3.868% 1Y -2.346%
Confidence100%
Low leverage (D/E)No promoter pledge
#214
View details ➜
P
Pharmaids Pharmaceuticals Ltd
Score 48/100• Decent
Pharmaids Pharmaceuticals Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics.
Company’s Health58/100
Valuation 40/100 · PB 3.1647
Technical Avoid
1M 2.205% 6M -14.828% 1Y -15.57%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#215
View details ➜
P
Parabolic Drugs Ltd
Score 48/100• Risky
Parabolic Drugs Ltd presents several risks with limited growth prospects and high valuation concerns, making it a risky investment.
Company’s Health14/100
Valuation 100/100 · PB -0.0398
Technical Avoid
1M 0% 6M 0% 1Y 0%
Confidence100%
Reasonable PB valuation
Promoter pledge presentThin margins
#216
View details ➜
O
Oxygenta Pharmaceutical Ltd
Score 48/100• Risky
Oxygenta Pharmaceutical Ltd shows potential but faces significant risks and challenges in the current market environment.
Company’s Health71/100
Valuation 100/100 · PB -8.8876
Technical Avoid
1M -0.243% 6M -49.663% 1Y -32.609%
Confidence100%
No promoter pledgeDecent revenue growth
Thin margins
#217
View details ➜
O
Orchid Pharma Ltd
Score 48/100• Risky
Orchid Pharma Ltd presents several risks with inconsistent growth and high debt levels, making it a risky investment.
Company’s Health72/100
Valuation 40/100 · PB 3.4016
Technical Watch
1M 14.53% 6M 17.942% 1Y -49.982%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#218
View details ➜
N
Novelix Pharmaceuticals Ltd
Score 48/100• Risky
Novelix Pharmaceuticals Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns.
Company’s Health64/100
Valuation 20/100 · PB 5.3549
Technical Avoid
1M 6.118% 6M 98.398% 1Y 140.952%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#219
View details ➜
N
Norris Medicines Ltd
Score 48/100• Risky
Norris Medicines Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health37/100
Valuation 100/100 · PB -1.0734
Technical Avoid
1M -14.706% 6M -15.429% 1Y -24.835%
Confidence100%
No promoter pledgeReasonable PB valuation
Thin margins
#220
View details ➜
M
Morepen Laboratories Ltd
Score 48/100• Risky
Morepen Laboratories Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
Company’s Health75/100
Valuation 80/100 · PB 1.9163
Technical Avoid
1M -11.011% 6M -37.116% 1Y -53.016%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#221
View details ➜
M
Mono Pharmacare Ltd
Score 48/100• Risky
Mono Pharmacare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health67/100
Valuation 80/100 · PB 1.0067
Technical Avoid
1M -8.802% 6M -28.8% 1Y -49.215%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEHigh debt/equity
#222
View details ➜
M
Mercury Laboratories Ltd
Score 48/100• Risky
Mercury Laboratories Ltd shows potential but faces significant risks and inconsistencies in growth and profitability.
Company’s Health68/100
Valuation 80/100 · PB 1.8709
Technical Avoid
1M -5.641% 6M -0.304% 1Y -14.802%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#223
View details ➜
M
Magenta Lifecare Ltd
Score 48/100• Decent
Magenta Lifecare Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
Company’s Health62/100
Valuation 100/100 · PB 0.6465
Technical Avoid
1M -0.377% 6M -17.868% 1Y -52.708%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#224
View details ➜
L
Lyka Labs Ltd
Score 48/100• Risky
Lyka Labs Ltd presents several risks with inconsistent financial performance and valuation concerns, making it a risky investment at this time.
Company’s Health72/100
Valuation 60/100 · PB 2.6493
Technical Avoid
1M -15.503% 6M -34.577% 1Y -53.244%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#225
View details ➜
Showing 211 to 225 of 260 (18 Pages)